The TCGA network identified a high frequency of TP53 mutations in ER‐negative, HER2‐positive breast cancers, whereas ER‐positive, HER2‐positive breast cancers displayed more often a GATA3 mutation (Koboldt et al., 2012). Here, ERBB2 is linked to breast carcinoma.